Trial · NCT00793585
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
NCT00793585, Not applicable, Completed, Sun Yat-sen University; results first posted 2011-07-01
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Controlled Study of Uric Acid on the Progression of IgA Nephropathy. Trials, record NCT00793585. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00793585
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
- NCT number
- NCT00793585
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- Sun Yat-sen University
- Conditions
- IgA Nephropathy
- Interventions
- allopurinol, continue their usual therapy
- First posted
- 2008-11-19
- Last updated
- 2016-05-25
- Results first posted
- 2011-07-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Renal Function as Measured With eGFR | baseline and 6 months | |
| Secondary | The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). | baseline and 6 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Renal Function as Measured With eGFR | baseline and 6 months | eGFR(min/ml) | MEAN | |
| SECONDARY | The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). | baseline and 6 months | We analysed all patient's data according to the ITT rule.And used the LOCF as the imputation technique. | Upro/cr (mg/g) | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Renal Function as Measured With eGFR | Control Group | 68.9 | Standard Deviation 36.6 | eGFR(min/ml) | |
| Change in Renal Function as Measured With eGFR | Allopurinol Group | 73.2 | Standard Deviation 34.8 | eGFR(min/ml) | |
| The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). | Control Group | 1170.4 | Standard Deviation 951.9 | Upro/cr (mg/g) | |
| The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). | Allopurinol Group | 1219.3 | Standard Deviation 1063.6 | Upro/cr (mg/g) |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Control Group | 19 | |
| Overall Study | STARTED | Allopurinol Group | 21 | |
| Overall Study | COMPLETED | Control Group | 17 | |
| Overall Study | COMPLETED | Allopurinol Group | 18 | |
| Overall Study | NOT COMPLETED | Control Group | 2 | |
| Overall Study | NOT COMPLETED | Allopurinol Group | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control Group | ||
| Total, all-cause mortality | Allopurinol Group | ||
| Total, other adverse events | Control Group | 0 | 19 |
| Total, other adverse events | Allopurinol Group | 0 | 21 |
| Total, serious adverse events | Control Group | 0 | 19 |
| Total, serious adverse events | Allopurinol Group | 0 | 21 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38299639 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Allopurinol Group vs Control Group: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00793585
GET https://conductscience.org/api/trials/v1/NCT00793585/registered